Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin therapy:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin therapy
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dosage of this drug is the patient's current dose of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this drug.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used by adjusting the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used in conjunction with meal and exercise therapy to assist patients with type 2 diabetes in controlling their blood sugar levels by taking Linagliptin and Metformin together. Through this, it effectively manages blood sugar, aiding in the treatment of diabetes.
How to take
Adult dose
In antidiabetic therapy, the dosage of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin therapy:
The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin therapy
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate, if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dosage of this drug is the patient's current dose of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dosage adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this drug.
No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used by adjusting the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.
Precautions
This medication can cause a rare side effect known as severe lactic acidosis; therefore, if any symptoms occur, an immediate visit to a hospital is necessary.
Patients with allergies to any component contained in this medication or those with specific conditions like type 1 diabetes, lactic acidosis, or diabetic ketoacidosis should not use it.
It is contraindicated for patients with severely impaired kidney function or those in a condition where acute changes in kidney function are expected.
Patients with severely compromised heart function, severe lung disease, or liver dysfunction should also refrain from using this medication for safety reasons.
Patients with acute or chronic alcohol intoxication, very poor nutritional status, or weakness should also avoid this medication.
Due to the risk of hypoglycemia, especially when used in conjunction with other antidiabetic agents, periodic blood sugar checks and dosage adjustments may be necessary.
To reduce the risk of lactic acidosis, it is advised to temporarily discontinue this medication during situations affecting kidney function, such as dehydration, severe infections, prior or post-surgery, and prior or post-use of radiologic contrast agents.
This medication is primarily excreted through the kidneys; hence, regular kidney function tests should be conducted before and during treatment, and elderly patients should be monitored carefully for kidney function.
There may be occurrences of acute pancreatitis or skin blistering diseases; thus, if persistent severe abdominal pain or skin abnormality symptoms develop, consult a doctor immediately.
Long-term use may lead to vitamin B12 deficiency, so if anemia or neurological symptoms appear, vitamin B12 levels should be assessed.
The tablets must not be chewed, crushed, or divided, but swallowed whole, and it is normal for the tablet shell to be excreted in the stool.
When using in conjunction with other medications, interaction possibilities exist; inform your physician or pharmacist about any current medications.
It is advisable not to use this medication during pregnancy or breastfeeding, and if planning to conceive, appropriate treatment should be discussed with a doctor.
Safety and efficacy concerning children have not been established; therefore, its use is not recommended.
In case of overdose, serious side effects like lactic acidosis can occur; seek appropriate medical treatment immediately.
Side effects
Severe lactic acidosis
hypoglycemia
nasopharyngitis
hypersensitivity reactions
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemia
taste disturbance
Show 127 moreCollapse
cough
loss of appetite
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcers
abnormal liver function tests
hepatitis
itching
erythema
rash
similar to pemphigus
severe and disabling arthralgia
rhabdomyolysis
increased lipase
increased amylase
constipation
upper abdominal pain
enterocolitis
intestinal obstruction
gastroenteritis
shingles
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer-type dementia
chest pain
fever
facial swelling
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastases
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
rectal cancer
pancreatic cancer
meniscus damage
pneumoconiosis
congestive heart failure
angina
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
kidney transplant failure
anxiety
affective disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
palpitations
dry eye
glaucoma
cataract
ocular discomfort
allergic conjunctivitis
polyuria
proteinuria
stress urinary incontinence
hematuria
hypotension
flushing
hepatic steatosis
cholelithiasis
hearing loss
erectile dysfunction
thyroid enlargement
anemia
nausea
gastroesophageal reflux disease
gastritis
viral upper respiratory infection
upper respiratory infection
periodontitis
dizziness
chest discomfort
weakness
nosebleed
oropharyngeal pain
voice disturbance
epistaxis
runny nose
osteoarthritis
limb pain
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgia
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
male pattern baldness
hyperhidrosis
dermatitis
anxiety
confused state
nocturia
dermatitis
hypertension
Not everyone experiences these, and they can vary from person to person.
Storage
Store the medication in a tightly closed container to protect it from air and moisture, and keep it at temperatures between 1°C and 30°C. This way, the effectiveness of the medication can be maintained for a longer period.
Appearance and packaging
Appearance
Oval-shaped extended-release tablet with one side inscribed with LK2, white to almost white.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.